Incobotulinumtoxina

Summary

Incobotulinumtoxina (CHEMBL2108035) is an approved unknown; indicated across 20 conditions including benign essential blepharospasm and stroke disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 20 conditions
• Clinical trials: 34

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108035
Name	Incobotulinumtoxina
Type	Unknown
Max phase	4

Also known as: Incobotulinumtoxina, RTI-150, RTI150, INCOBOTULINUMTOXINA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

14 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
benign essential blepharospasm	3	MONDO:0011728	Orphanet:93955
stroke disorder	3	MONDO:0005098	EFO:0000712
overactive bladder	3	MONDO:0006624	EFO:1000781
dystonic disorder	3	MONDO:0003441	MONDO:0003441
Parkinson disease	3	MONDO:0005180	MONDO:0005180
bruxism	3	MONDO:0002443	MONDO:0002443
essential tremor	2	MONDO:0003233	EFO:0003108
trigeminal neuralgia	2	MONDO:0008599	EFO:1001219
rosacea	2	MONDO:0006604	EFO:1000760
sleep apnea syndrome	2	MONDO:0005296	EFO:0003877
borderline personality disorder	2	MONDO:0001156	HP:0012076
androgenetic alopecia	2	MONDO:0005339	EFO:0004191
cerebral palsy	2	MONDO:0006497	MONDO:0000396
diabetic neuropathy	2	MONDO:0006626	EFO:1000783

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 34.

Phase distribution

Phase	Trials
PHASE3	12
PHASE2	10
PHASE4	6
Not specified	3
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03855046	PHASE4	RECRUITING	Complex Treatment of a Chronic Anal Fissure
NCT01583478	PHASE4	UNKNOWN	Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids
NCT02096081	PHASE4	COMPLETED	The Treatment of Glabellar Frown Lines
NCT03044080	PHASE4	COMPLETED	Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot
NCT05536570	PHASE4	UNKNOWN	Whiplash-induced Thoracic Outlet Syndrome Treated With Botulinum Toxin.
NCT06250543	PHASE4	COMPLETED	Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder
NCT05598723	PHASE3	RECRUITING	BOTOX® vs. XEOMIN® for Chronic Migraine
NCT00406367	PHASE3	COMPLETED	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
NCT00432666	PHASE3	COMPLETED	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb
NCT00541723	PHASE3	COMPLETED	Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles
NCT01392300	PHASE3	COMPLETED	Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
NCT01464307	PHASE3	COMPLETED	Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
NCT01603459	PHASE3	COMPLETED	Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
NCT01893411	PHASE3	COMPLETED	Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
NCT01905683	PHASE3	COMPLETED	Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
NCT02002884	PHASE3	COMPLETED	Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
NCT02091739	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
NCT03758235	PHASE3	UNKNOWN	Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin
NCT07537855	PHASE2	NOT_YET_RECRUITING	Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction
NCT01515371	PHASE2	TERMINATED	Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring
NCT01614743	PHASE2	COMPLETED	A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
NCT01931865	PHASE2	TERMINATED	IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation
NCT01931878	PHASE2	COMPLETED	Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.
NCT02088632	PHASE2	TERMINATED	Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia
NCT02207946	PHASE2	COMPLETED	Botulinum Toxin A to Treat Arm Tremor
NCT02419313	PHASE2	COMPLETED	Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson’s Tremor: A Customized Approach
NCT05340439	PHASE2	UNKNOWN	INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)
NCT06091020	PHASE2	COMPLETED	A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury
NCT05585398	PHASE1	COMPLETED	A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods
NCT06604832	PHASE1	COMPLETED	Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture
NCT05305768	EARLY_PHASE1	UNKNOWN	Xeomin Treatment of Glabellar Lines Using OLD Versus COLD
NCT04290169	Not specified	UNKNOWN	Effect of Video Game-assisted and BoNT-A Injection Therapy on Spasticity, Activity and Participation in CP Patients
NCT05167864	Not specified	COMPLETED	Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
NCT05222607	Not specified	TERMINATED	Longitudinal Evaluation and Real-world Evidence of NT201

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).